IQWiG

Drug assessment at a glance: A26-58[1]

Blinatumomab (B-ALL, refractory or relapsed, children and adolescents ≥1 month)

6 November 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-58. The GBA decides on the added benefit.

Research question for the benefit assessment

Population	Paediatric patients aged 1 month or older with Ph- CD19+ B-cell precursor ALL which is refractory or in relapse after receiving at least 2 prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation
Intervention	blinatumomab
Comparator	Individualised treatment, selecting from ▪ tisagenlecleucel ▪ Systemic chemotherapy with ▫ asparaginase, cytarabine, dexamethasone, mercaptopurine, methotrexate, prednisolone, vincristine ▫ asparaginase, cytarabine, daunorubicin, dexamethasone, ifosfamide, methotrexate, prednisolone, thioguanine, vindesine ▫ asparaginase, cytarabine, dexamethasone, etoposide, methotrexate, prednisolone ▫ clofarabine, cyclophosphamide and etoposide ▫ cyclophosphamide, etoposide, methotrexate, intrathecal methotrexate, G-CSF ▫ dexamethasone, vincristine, methotrexate (high-dose), cyclophosphamide, ara-C (high-dose), pegasparaginase / Erwinia asparaginase [HC1] ▫ dexamethasone, vindesine, methotrexate (high-dose), ifosfamide, daunorubicin, pegasparaginase / Erwinia asparaginase [HC2] ▫ dexamethasone, ara-C (high-dose), etoposide, pegasparaginase / Erwinia asparaginase [HC3] ▫ cytarabine, fludarabine, G-CSF ± idarubicin ▫ dexamethasone, mitoxantrone, PEG-asparaginase, vincristine ▫ dexamethasone, doxorubicin, PEG-asparaginase, vincristine ▫ doxorubicin, PEG-asparaginase, prednisone, vincristine, intrathecal cytarabine, intrathecal methotrexate ▫ L-asparaginase, cytarabine, G-CSF ▫ pegaspargase, prednisone or dexamethasone, venetoclax, vincristine
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Blinatumomab (B-ALL, refraktär oder rezidiviert, Kinder und Jugendliche ≥ 1 Monat); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 03.11.2026]. URL: https://doi.org/10.60584/A26-58.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, rezidiviert / refraktär, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation, Kinder ≥ 1 Monat) [online]. 2026 [Accessed: 03.11.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1348/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-58.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de